About Q Therapeutics

Q Therapeutics is an emerging biopharmaceutical company that utilizes cell-based technologies to develop new treatments for debilitating diseases of the central nervous system (CNS). In 2004, we began the process of translating decades of research at the University of Utah, Cornell Medical College, and the National Institute of Health (NIH) into practical new therapeutic products. Our exclusive licenses with these institutions have resulted in 16 issued patents, with many more pending.

Q's initial development efforts have focused on natural cell-based products that replace insulating myelin on damaged neurons, with the goal of restoring normal neuron function. Our first product, called Q-Cells™, is designed to address a wide range of diseases, including multiple sclerosis (MS), transverse myelitis, cerebral palsy, spinal cord injury, and certain types of stroke. Our patented cellular technologies and manufacturing processes, combined with an experienced management team and a focused strategy, will enable us to develop a comprehensive product pipeline to treat CNS diseases in ways no existing drug can.

Q has patents covering cells that give rise to the entire central nervous system. Both Q-Cells and other of Q's cell types can be made available under collaborative research or licensing arrangements.